Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00550862 · ClinicalTrials.gov registry record · Phase 2
Study of INT 747 in Combination With URSO in Patients With Primay Biliary Cirrhosis (PBC)
A Phase 2 study, sponsored by Intercept Pharmaceuticals.
- Terminated
- Registry status
- Phase 2
- Development phase
- 165
- Enrollment target
NCT00550862 is a Phase 2 study that was terminated before completion, run by Intercept Pharmaceuticals. The registered enrollment target is 165 participants.
The verdict
NCT00550862, a Phase 2 study, was terminated before completion, sponsored by Intercept Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 165 participants
- Enrollment target
Study Summary
The primary hypothesis is that INT-747 will cause a reduction in alkaline phosphatase levels in Primary Biliary Cirrhosis patients, over a 12 week treatment period, as compared to placebo.
Interventions
- DRUG Placebo
- DRUG INT-747
- DRUG Ursodeoxycholic Acid (URSO)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 165 participants |
| Start Date | 2007-10 |
| Est. Completion | 2010-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00550862
The ClinicalTrials.gov registry entry for NCT00550862 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 165 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Intercept Pharmaceuticals, which has 18 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT00550862 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00550862 about?
NCT00550862 is a clinical study titled "Study of INT 747 in Combination With URSO in Patients With Primay Biliary Cirrhosis (PBC)". The primary hypothesis is that INT-747 will cause a reduction in alkaline phosphatase levels in Primary Biliary Cirrhosis patients, over a 12 week treatment period, as compared to placebo.
What is the current status of trial NCT00550862?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 165 participants. The study started on 2007-10. Estimated completion is 2010-12.
What interventions are being tested in trial NCT00550862?
The interventions under investigation include: Placebo (DRUG), INT-747 (DRUG), Ursodeoxycholic Acid (URSO) (DRUG).
Who is sponsoring clinical trial NCT00550862?
This trial is sponsored by Intercept Pharmaceuticals, which has 18 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.